Abstract
Malignant glioma (MG) represents the most prevalent and lethal primary central nervous system cancer. Despite aggressive surgical resection and treatment regimens, patients diagnosed with the highest grade MG, grade IV glioblastoma multiforme (GBM), survive for only 9–12 months after diagnosis. Multimodal approaches using radiation with conjunctive chemotherapy (temozolamide) resulted in only marginal increase in patients’ survival up to 14.6 months. An incomplete understanding of how catalogued genetic aberrations dictate phenotypic hallmarks of the disease, particularly intense therapy (apoptosis) resistance, yet florid intratumoral necrogenesis, combined with a highly therapy-resistant cancer stem cell population (brain tumor stem cells, BTSC) as the putative cell-of-origin conspired to make GBM a highly enigmatic and incurable disease. Especially the continued lack of success in treating high-grade gliomas with targeted (receptor) tyrosine kinase inhibitors, which have been proven to be effective in other malignancies, has prompted a reevaluation of all aspects of glioma drug development and underlined the overarching need to identify and molecularly dissect genetic aberrations in cellular survival pathways that play pivotal roles in GBM’s profound therapy resistance. This review focuses on apoptosis and necrosis pathways implicated in GBM development and evasion from therapy-induced cell death, and discusses the roles and potential therapeutical applications of the novel Bcl-2-like oncoprotein Bcl2L12 in driving cell death-related phenotypes in GBM.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alcantara Llaguno S, Chen J, Kwon CH, Jackson EL, Li Y, Burns DK, Alvarez-Buylla A, Parada LF (2009) Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 15:45–56
Arrigo AP, Simon S, Gibert B, Kretz-Remy C, Nivon M, Czekalla A, Guillet D, Moulin M, Diaz-Latoud C, Vicart P (2007) Hsp27 (HspB1) and alphaB-crystallin (HspB5) as therapeutic targets. FEBS Lett 581:3665–3674
Brat DJ, Van Meir EG (2004) Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest 84:397–405
Cheng WC, Berman SB, Ivanovska I, Jonas EA, Lee SJ, Chen Y, Kaczmarek LK, Pineda F, Hardwick JM (2006) Mitochondrial factors with dual roles in death and survival. Oncogene 25:4697–4705
Corsini NS, Sancho-Martinez I, Laudenklos S, Glagow D, Kumar S, Letellier E, Koch P, Teodorczyk M, Kleber S, Klussmann S, Wiestler B, Brustle O, Mueller W, Gieffers C, Hill O, Thiemann M, Seedorf M, Gretz N, Sprengel R, Celikel T, Martin-Villalba A (2009) The death receptor CD95 activates adult neural stem cells for working memory formation and brain repair. Cell Stem Cell 5:178–190
Eckelman BP, Salvesen GS, Scott FL (2006) Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 7:988–994
Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21:2683–2710
Green DR, Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science 305:626–629
Green DR, Kroemer G (2009) Cytoplasmic functions of the tumour suppressor p53. Nature 458:1127–1130
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70
Harris SL, Levine AJ (2005) The p53 pathway: positive and negative feedback loops. Oncogene 24:2899–2908
Hotchkiss RS, Strasser A, McDunn JE, Swanson PE (2009) Cell death. N Engl J Med 361:1570–1583
Johnson ce, Huang YY, Parrish AB, Smith MI, Vaughn AE, Zhang Q, Wright KM, Van Dyke T, Wechsler-Reya RJ, Kornbluth S, Deshmukh M (2007) Differential apaf-1 levels allow cytochrome c to induce apoptosis in brain tumors but not in normal neural tissues. Proc Natl Acad Sci USA 104:20820–20825
Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O, Thiemann M, Mueller W, Sykora J, Kuhn A, Schreglmann N, Letellier E, Zuliani C, Klussmann S, Teodorczyk M, Grone HJ, Ganten TM, Sultmann H, Tuttenberg J, von Deimling A, Regnier-Vigouroux A, Herold-Mende C, Martin-Villalba A (2008) Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 13:235–248
Kwon CH, Zhao D, Chen J, Alcantara S, Li Y, Burns DK, Mason RP, Lee EY, Wu H, Parada LF (2008) Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res 68:3286–3294
Mareninova OA, Sung KF, Hong P, Lugea A, Pandol SJ, Gukovsky I, Gukovskaya AS (2006) Cell death in pancreatitis: caspases protect from necrotizing pancreatitis. J Biol Chem 281:3370–3381
Nicotera P, Melino G (2004) Regulation of the apoptosis-necrosis switch. Oncogene 23:2757–2765
Scorilas A, Kyriakopoulou L, Yousef GM, Ashworth LK, Kwamie A, Diamandis EP (2001) Molecular cloning, physical mapping, and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved BH2 domain of the bcl-2 family. Genomics 72:217–221
Stegh AH, Brennan C, Mahoney JA, Folrloney KL, Jenq HT, Protopopov A, Chin L, DePinho RA (2010). Glioma Oncoprotein Bcl2L12 inhibits the p53 tumor suppressor. Genes Dev 24:2194–2204
Stegh AH, Chin L, Louis DN, DePinho RA (2008a) What drives intense apoptosis resistance and propensity for necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional cell death regulator. Cell Cycle 7:2833–2839
Stegh AH, Kesari S, Mahoney JE, Jenq HT, Forloney KL, Protopopov A, Louis DN, Chin L, DePinho RA (2008b) Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Proc Natl Acad Sci USA 105:10703–10708
Stegh AH, Kim H, Bachoo RM, Forloney KL, Zhang J, Schulze H, Park K, Hannon GJ, Yuan J, Louis DN, DePinho RA, Chin L (2007) Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev 21:98–111
Stegh AH, Peter ME (2001) Apoptosis and caspases. Cardiol Clin 19:13–29
Stiles CD, Rowitch DH (2008) Glioma stem cells: a midterm exam. Neuron 58:832–846
The Cancer Genome Atlas Research Network, (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061–1068
Watanabe T, Hirota Y, Arakawa Y, Fujisawa H, Tachibana O, Hasegawa M, Yamashita J, Hayashi Y (2003) Frequent LOH at chromosome 12q22-23 and apaf-1 inactivation in glioblastoma. Brain Pathol 13:431–439
Youle RJ, Strasser A (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9:47–59
Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, Stommel JM, Dunn KL, Wiedemeyer R, You MJ, Brennan C, Wang YA, Ligon KL, Wong WH, Chin L, DePinho RA (2008) P53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455:1129–1133
Ziegler DS, Kung AL, Kieran MW (2008) Anti-apoptosis mechanisms in malignant gliomas. J Clin Oncol 26:493–500
Zong WX, Thompson CB (2006) Necrotic death as a cell fate. Genes Dev 20:1–15
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Stegh, A.H. (2011). Cell Death Signaling in Glioblastoma Multiforme: Role of the Bcl2L12 Oncoprotein. In: Hayat, M. (eds) Tumors of the Central Nervous System, Volume 1. Tumors of the Central Nervous System, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-0344-5_16
Download citation
DOI: https://doi.org/10.1007/978-94-007-0344-5_16
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-0343-8
Online ISBN: 978-94-007-0344-5
eBook Packages: MedicineMedicine (R0)